试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-12-03
SWC for Treatment of Superficial Partial-Thickness Burns
编号:NCT05877638登记状态:提前终止企业 / 申办者:Synedgen, Inc.
药物 / 成分:SynePure Wound Cleanser and Catasyn Advanced Technology Hydrogel、SILVADENE Cream 1% (silver sulfadiazine)
登记的停止原因(原文):Lack of enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-12-03
Study of the Safety, Tolerability, and PK of SZEY-2108 Administered Intravenously to HVs in SAD and MAD Cohorts
编号:NCT06055777登记状态:提前终止企业 / 申办者:Suzhou Erye Pharmaceutical Co., Ltd.
药物 / 成分:SZEY-2108 for injetion、Placebo
登记的停止原因(原文):Due to the termination criteria for dose escalation in the clinical protocol having been reached, this trial is terminated.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-12-02
Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144
编号:NCT02403323登记状态:提前终止企业 / 申办者:Hoffmann-La Roche
药物 / 成分:Etrolizumab
登记的停止原因(原文):The study was terminated due to program discontinuation, based on mixed efficacy results in the parent studies. There were no safety concerns.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-12-02
Safety and Efficacy of Medical Cannabis Oil in the Treatment of Patients with Chronic Pain
编号:NCT03337503登记状态:提前终止企业 / 申办者:Santé Cannabis
药物 / 成分:THC and CDB in a 1 to 1 ratio、Experimental: THC and CBD in a 1 to 2 ratio、High CBD with trace THC oil、placebo
登记的停止原因(原文):Sponsor decision to stop the study
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-12-02
TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors
编号:NCT03387917登记状态:提前终止企业 / 申办者:Swiss Cancer Institute
药物 / 成分:TLD-1、Caelyx
登记的停止原因(原文):The premature termination is based on the unexpectedly low patient accrual to the clinical trial and the strategic considerations in the development of the TLD-1 after having included 13 out of 14 patients in the comparative PK part.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-12-02
Comparison of Two Multimodal Analgesia Regimens in Total Knee Arthroplasty
编号:NCT03990038登记状态:提前终止企业 / 申办者:Ciusss de L'Est de l'Île de Montréal
药物 / 成分:Continuous perineural infusion of ropivacaine 0.2% 5 ml/h for 48 h、Extended Release Capsule
登记的停止原因(原文):Recruitment problems making the study completion unlikely
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-12-02
Plitidepsin Versus Control in Immunocompromised Adult Participants With Symptomatic COVID-19 Requiring Hospital Care (NEREIDA)
编号:NCT05705167登记状态:提前终止企业 / 申办者:PharmaMar
药物 / 成分:Plitidepsin
登记的停止原因(原文):Significant difficulties in the recruitment of participants.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-29
NEPHSTROM for Diabetic Kidney Disease
编号:NCT02585622登记状态:提前终止企业 / 申办者:Mario Negri Institute for Pharmacological Research
药物 / 成分:Mesenchymal Stromal Cells、Placebo
登记的停止原因(原文):IMP NEPHSTROM ORBECEL-M is expired and additional extension is not feasible. Low recruitment rate at Birmingham center.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-29
Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis
编号:NCT04508140登记状态:提前终止企业 / 申办者:Highlight Therapeutics
药物 / 成分:Hepatic Biopsy、BO-112 with pembrolizumab
登记的停止原因(原文):Low recruitment rate
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-29
A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.
编号:NCT04612790登记状态:提前终止企业 / 申办者:AstraZeneca
药物 / 成分:Benralizumab、Placebo
登记的停止原因(原文):Independent Data Monitoring Committee recommended terminating the study following a pre-planned analysis as the efficacy results did not meet the pre-defined futility guidelines. There were no new safety concerns identified from this analysis.
查看官方原始记录 ↗